State Ledger
Company profile

Inhibikase Therapeutics, Inc. CIK 1750149

Ticker
IKT (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Wilmington, DE 19801
Fiscal year end
2025 (FY)
Market Data
Close
$1.76
Change
-$0.08
Change %
-4.35%
Volume
96,350

IKT · trading date Oct 13, 2026 · previous close $1.84 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$48.26M
Total assets
$181.20M
Total liabilities
$8.30M
Stockholders' equity
$172.90M
Cash & equivalents
$178.80M
Operating income
-$51.97M
Operating cash flow
-$27.79M
Capital expenditures
$13.4K

Fiscal year 2025, via 10-K filed 2026-03-26. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$27.80M
Free cash flow margin
—
Liabilities / assets
4.6%
Equity / assets
95.4%
CapEx / revenue
—
Operating cash flow / net income
0.58×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$48.26M $181.20M $8.30M $172.90M
2024 $0 -$27.52M $98.60M $3.73M $94.87M
2023 $260.5K -$19.03M $14.51M $3.53M $10.98M
2022 $123.4K -$18.05M $24.94M $3.90M $21.04M
2021 $3.10M -$14.79M $42.47M $4.05M $38.42M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-09-08
Financials filed via
Form 10-K
filed 2026-03-26

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Wilmington, DE 19801
1000 N. WEST STREET, SUITE 1200
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:23 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Delaware — Public Companies